Frequently Asked Questions

Use the below list of FAQs to learn more about MAGNITUDE-2 study topics.

Table of Contents:

• Key Patient Reminders

• Crossover Considerations

• Reordering Materials

What are the key reminders I need to communicate to participants?

• Attend all study appointments
• Do not take the at-home corticosteroid medication unless you instruct them to do so. Most patients will not need to take this medication.
• Watch for warning signs such as weakness/fatigue, muscle aching, fever, chills, nausea, vomiting, stomach pain, loss of appetite, jaundice, or dark urine.
• Avoid alcohol, new or changing medications, and use of acetaminophen for the first 2 month of study drug infusion.

What considerations should I remember for crossover assessment?

• Abstention from alcohol is required for 64 days post crossover dose (for consideration especially around holidays).
• Planned initiation of potentially hepatoxic therapies is not allowed within 64 days of crossover dosing.
• Crossover should not yet be pursued if there is anticipation of antithrombotic therapy with warfarin or heparin/heparin derivatives within 14 days prior to dosing through day 64.
• Take into account vaccination schedules. Vaccines are not allowed through 28 days after crossover dosing.

How do I reorder study materials/supplies?

Fill out the linked form below to request additional study items.